Romina Libster1, Monica McNeal2, Emmanuel B Walter3, Andi L Shane4, Patricia Winokur5, Gretchen Cress5, Andrea A Berry6, Karen L Kotloff6, Kwabena Sarpong7, Christine B Turley7, Christopher J Harrison8, Barbara A Pahud8, Jyothi Marbin9, John Dunn10, Jill El-Khorazaty11, Jill Barrett11, Kathryn M Edwards12. 1. Department of Pediatrics, Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, Nashville, Tennessee; Fundación INFANT, CABA, Argentina; National Scientific and Technical Research Council (CONICET), CABA, Argentina; 2. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; 3. Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina; 4. Emory University School of Medicine, Atlanta, Georgia; 5. University of Iowa, Iowa City, Iowa; 6. Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; 7. The University of Texas Medical Branch, Galveston, Texas; 8. Children's Mercy Hospital, Kansas City, Missouri; 9. UCSF Benioff Children's Hospital Oakland, California; 10. Group Health Cooperative, Seattle, Washington; and. 11. Emmes Corporation, Rockville, Maryland. 12. Department of Pediatrics, Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, Nashville, Tennessee; kathryn.edwards@vanderbilt.edu.
Abstract
BACKGROUND AND OBJECTIVES: Although both licensed rotavirus vaccines are safe and effective, it is often not possible to complete the schedule by using the same vaccine formulation. The goal of this study was to investigate the noninferiority of the immune responses to the 2 licensed rotavirus vaccines when administered as a mixed schedule compared with administering a single vaccine formulation alone. METHODS: Randomized, multicenter, open-label study. Healthy infants (6-14 weeks of age) were randomized to receive rotavirus vaccines in 1 of 5 different schedules (2 using a single vaccine for all doses, and 3 using mixed schedules). The group receiving only the monovalent rotavirus vaccine received 2 doses of vaccine and the other 4 groups received 3 doses of vaccine. Serum for immunogenicity testing was obtained 1 month after the last vaccine dose and the proportion of seropositive children (rotavirus immunoglobulin A ≥20 U/mL) were compared in all the vaccine groups. RESULTS:Between March 2011 and September 2013, 1393 children were enrolled and randomized. Immune responses to all the sequential mixed vaccine schedules were shown to be noninferior when compared with the 2 single vaccine reference groups. The proportion of children seropositive to at least 1 vaccine antigen at 1 month after vaccination ranged from 77% to 96%, and was not significantly different among all the study groups. All schedules were well tolerated. CONCLUSIONS: Mixed schedules are safe and induced comparable immune responses when compared with the licensed rotavirus vaccines given alone.
RCT Entities:
BACKGROUND AND OBJECTIVES: Although both licensed rotavirus vaccines are safe and effective, it is often not possible to complete the schedule by using the same vaccine formulation. The goal of this study was to investigate the noninferiority of the immune responses to the 2 licensed rotavirus vaccines when administered as a mixed schedule compared with administering a single vaccine formulation alone. METHODS: Randomized, multicenter, open-label study. Healthy infants (6-14 weeks of age) were randomized to receive rotavirus vaccines in 1 of 5 different schedules (2 using a single vaccine for all doses, and 3 using mixed schedules). The group receiving only the monovalent rotavirus vaccine received 2 doses of vaccine and the other 4 groups received 3 doses of vaccine. Serum for immunogenicity testing was obtained 1 month after the last vaccine dose and the proportion of seropositive children (rotavirus immunoglobulin A ≥20 U/mL) were compared in all the vaccine groups. RESULTS: Between March 2011 and September 2013, 1393 children were enrolled and randomized. Immune responses to all the sequential mixed vaccine schedules were shown to be noninferior when compared with the 2 single vaccine reference groups. The proportion of children seropositive to at least 1 vaccine antigen at 1 month after vaccination ranged from 77% to 96%, and was not significantly different among all the study groups. All schedules were well tolerated. CONCLUSIONS: Mixed schedules are safe and induced comparable immune responses when compared with the licensed rotavirus vaccines given alone.
Authors: Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: W Katherine Yih; Tracy A Lieu; Martin Kulldorff; David Martin; Cheryl N McMahill-Walraven; Richard Platt; Nandini Selvam; Mano Selvan; Grace M Lee; Michael Nguyen Journal: N Engl J Med Date: 2014-01-14 Impact factor: 91.245
Authors: Catherine A Panozzo; Sylvia Becker-Dreps; Virginia Pate; Michele Jonsson Funk; Til Stürmer; David J Weber; M Alan Brookhart Journal: PLoS One Date: 2013-09-16 Impact factor: 3.240
Authors: R Chilengi; K Mwila-Kazimbaya; M Chirwa; N Sukwa; C Chipeta; R M Velu; N Katanekwa; S Babji; G Kang; M M McNeal; N Meyer; G Gompana; S Hazra; Y Tang; J Flores; N Bhat; N Rathi Journal: Vaccine Date: 2021-05-12 Impact factor: 3.641